1149-26-4 Usage
Description
N-Carbobenzyloxy-L-valine, commonly referred to as N-Cbz-L-valine, is an N-Cbz-protected form of L-Valine (V094205). L-Valine is an essential amino acid that plays a crucial role in various biological processes. N-Cbz-L-valine is a white to light yellow crystalline powder, which is widely used in the synthesis of pharmaceuticals and other applications due to its unique chemical properties.
Uses
1. Used in Pharmaceutical Industry:
N-Carbobenzyloxy-L-valine is used as an intermediate for the synthesis of various pharmaceutical compounds, such as Imatinib and Valaciclovir. These drugs are used for the treatment of different medical conditions, with Imatinib being a tyrosine kinase inhibitor for the treatment of certain types of cancer, and Valaciclovir being an antiviral medication used to treat herpes simplex and herpes zoster.
2. Used in Cosmetic Industry:
N-Carbobenzyloxy-L-valine is used as an ingredient in cosmetic formulations due to its beneficial properties for skin health. As an essential amino acid, L-valine contributes to the maintenance and repair of skin tissues, promoting a healthy and youthful appearance.
3. Used in Animal Feed Industry:
N-Carbobenzyloxy-L-valine is also used in the animal feed industry as a supplement to provide essential amino acids for the growth and development of animals. L-valine plays a vital role in the growth and ammonia detoxification processes in humans, and its inclusion in animal feed ensures that livestock receive the necessary nutrients for optimal health and productivity.
4. Used in Research and Development:
N-Carbobenzyloxy-L-valine serves as a valuable compound in research and development for the discovery and development of new drugs and therapies. Its unique chemical properties make it an attractive candidate for the synthesis of novel pharmaceutical compounds with potential applications in various medical fields.
Synthesis Reference(s)
Synthesis, p. 738, 1985 DOI: 10.1055/s-1985-31329
Check Digit Verification of cas no
The CAS Registry Mumber 1149-26-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,4 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1149-26:
(6*1)+(5*1)+(4*4)+(3*9)+(2*2)+(1*6)=64
64 % 10 = 4
So 1149-26-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H17NO4/c1-9(2)11(12(15)16)14-13(17)18-8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3,(H,14,17)(H,15,16)/p-1/t11-/m0/s1
1149-26-4Relevant articles and documents
-
Fox et al.
, p. 1862 (1950)
-
Design and synthesis of novel symmetric fluorene-2,7-diamine derivatives as potent hepatitis C virus inhibitors
Mousa, Mai H. A.,Ahmed, Nermin S.,Schwedtmann, Kai,Frakolaki, Efseveia,Vassilaki, Niki,Zoidis, Grigoris,Weigand, Jan J.,Abadi, Ashraf H.
, (2021/04/16)
Hepatitis C virus (HCV) is an international challenge. Since the discovery of NS5A direct-acting antivirals, researchers turned their attention to pursue novel NS5A inhibitors with optimized design and structure. Herein we explore highly potent hepatitis C virus (HCV) NS5A inhibitors; the novel analogs share a common symmetrical prolinamide 2,7-diaminofluorene scaffold. Modification of the 2,7-diaminofluorene backbone included the use of (S)-prolinamide or its isostere (S,R)-piperidine-3-caboxamide, both bearing different amino acid residues with terminal carbamate groups. Compound 26 exhibited potent inhibitory activity against HCV genotype (GT) 1b (effective concentration (EC50) = 36 pM and a selectivity index of >2.78 × 106). Compound 26 showed high selectivity on GT 1b versus GT 4a. Interestingly, it showed a significant antiviral effect against GT 3a (EC50 = 1.2 nM). The structure-activity relationship (SAR) analysis revealed that picomolar inhibitory activity was attained with the use of S-prolinamide capped with R- isoleucine or R-phenylglycine residues bearing a terminal alkyl carbamate group.
Enantioselective inclusion of pyrene-1-sulfonate salts of α-amino acids with crystals of α-cyclodextrin
Hattori, Tetsutaro,Kitamoto, Yuichi,Maeda, Tetsuya,Miyoshi, Ikuko,Morohashi, Naoya
supporting information, (2020/04/01)
Enantioselective inclusion of α-amino acids with crystals of α-cyclodextrin (α-CD) has been achieved by converting the amino acids into sulfonate salts with pyrene-1-sulfonic acid (PyS). For example, crystals of α-CD selectively include L-leucine/PyS (1:1) salt in a host/guest ratio of ~1 with 92%ee from a solution of the racemic salt in ethanol/N-methylformamide (91:9) at 40 °C. Under conditions optimized for individual amino acids, the PyS salts of valine, phenylalanine, and methionine are also included with good enantioselectivities (up to 86%ee). Mechanistic studies for the inclusion of leucine/PyS salt reveals that the enantioselectivity originates from the difference in stability between the inclusion complexes of D- and L-leucine/PyS salts with α-CD in crystals.